A Randomized, Phase II Study of CX-01 Combined with Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia (AML)

The purpose of this study is to find out whether or not the addition of the study drug, CX-01, to standard of care treatment for AML increases the rate of remission.

Primary Sponsor:
Cantex Pharmaceuticals, Inc.

Prinicipal Investigator:
Imad Tabbara, M.D./Medicine; Division of Hematology/Oncology

Contact Phone:
202-741-2981

Are you interested in more information on this clinical trial?

First Name *
Last Name *
Email *
Street Address *
City *
State *
Zip Code *
Phone Number 
     
Verification Code *

Please type what you see (all uppercase):